Role of leptin and its receptors in the pathogenesis of thyroid cancer

International Journal of Clinical and Experimental Pathology

Volumn 4, Issue 7, 2011, Pages 637-643

  Uddin, Shahab ^a   Hussain, Azhar R ^a   Siraj, Abdul K ^a   Khan, Omar S ^a   Bavi, Prashant P ^a   Al Kuraya, Khawla S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Leptin; Leptin receptors; Papillary thyroid carcinoma; Sinaling pathways

Indexed keywords

LEPTIN; LEPTIN RECEPTOR; LEPTIN RECEPTOR, HUMAN;

HUMAN; METABOLISM; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION; THYROID TUMOR;

HUMANS; LEPTIN; RECEPTORS, LEPTIN; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 81355139437     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Baratta M. Leptin-from a signal of adiposity to a hormonal mediator in peripheral tissues. Med Sci Monit 2002; 8: RA282-RA292.
2. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L and Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
3. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, Muir C, Sanker S, Moriarty A, Moore KJ, Smutko JS, Mays GG, Wool EA, Monroe CA and Tepper RI. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995; 83: 1263-1271.
4. Chua SC Jr, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia L and Leibel RL. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996; 16: 994-996.
5. Ahima RS and Flier JS. Leptin. Annu Rev Physiol 2000; 62: 413-437.
6. Lin J, Barb CR, Matteri RL, Kraeling RR, Chen X, Meinersmann RJ and Rampacek GB. Long form leptin receptor mRNA expression in the brain, pituitary, and other tissues in the pig. Domest Anim Endocrinol 2000; 19: 53-61.
7. Caprio M, Fabbrini E, Isidori AM, Aversa A and Fabbri A. Leptin in reproduction. Trends Endocrinol Metab 2001; 12: 65-72.
8. Ghilardi N, Ziegler S, Wiestner A, Stoffel R, Heim MH and Skoda RC. Defective STAT signaling by the leptin receptor in diabetic mice. Proc Natl Acad 1996; 93: 6231-6235.
9. Myers MG Jr. Leptin receptor signaling and the regulation of mammalian physiology, Rec Prog Horn Res 2004; 59: 287-304.
10. Eisenberg A, Biener E, Charlier M, Krishnan RV, Djiane J, Herman B and Gertler B. Transacfivation of erbB2 by short and long isoforms of leptin receptors. FEBSLell 2004; 565: 139-142.
11. Bjorbaek C, Uotani S, da Silva, B and Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem 1997; 272: 32686-32695.
12. Sobhani I, Bado A, Vissuzaine C, Buyse M, Kermorgant S, Laigneau J, Attoub PS, Lehy T, Henin D, Mignon M and Lewin MJ. Leptin secretion and leptin receptor in the human stomach. Gut 2000; 47: 178-183.
13. Bahrenberg G, Behrmann I, Barthel A, Hekerman P, Heinrich PC, Joost HG and Becker W. Identification of the critical sequence elements in the cytoplasmic domain of leptin receptor isoforms required for Janus kinase/signal transducer and activator of transcription activation by receptor heterodimers. Mol Endocrinol 2002; 16: 859-872.
14. Jaffe T and Schwartz B. Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways. Int J Cancer 2008; 123: 2543-2556.
15. Jiang L, Li Z and Rui L. Leptin stimulates both JAK2-dependent and JAK2-independent signaling pathways. J Biol Chem 2008; 283: 28066-28073.
16. Banks AS, Davis SM, Bates SH and Myers MG Jr. Activation of downstream signals by the long form of the leptin receptor. J Biol Chem 2000; 275: 14563-14572.
17. Bates SH, Stearns WH, Dundon TA, Schubert M, Tso AW, Wang Y, Banks AS, Lavery HJ, Haq AK, Maratos-Flier E, Neel BG, Schwartz MW and Myers MG Jr. STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature 2003; 421: 856-859.
18. da Silva BA, Bjørbaek C, Uotani S and Flier JS. Functional properties of leptin receptor isoforms containing the gln-->pro extracellular domain mutation of the fatty rat. Endocrinology 1998; 39: 3681-3690.
19. Bjørbaek C, Uotani S, da Silva B and Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem 1997; 272: 32686-32695.
20. Hoda MR, Keely SJ, Bertelsen LS, Junger WG, Dharmasena D and Barrett KE. Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. Br J Surg 2007; 94: 346-354.
21. Ogunwobi OO and Beales IL. The antiapoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3 kinase/AKT. Int J Colorectal Dis 2007; 22: 401-409.
22. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D and Anania FA. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 2007; 67: 2497-2507.
23. Sharma D, Saxena NK, Vertino PM and Anania FA. Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signaltransduction pathways. Endocr Relat Cancer 2006; 13: 629-640.
24. Rordorf-Nikolic T, Van Horn DJ, Chen D, White MF, Backer JM. Regulation of phosphatidylinositol 3'-kinase by tyrosyl phosphoproteins. Full activation requires occupancy of both SH2 domains in the 85-kDa regulatory subunit. J Biol Chem 1995; 270: 3662-3666.
25. Kane LP and Weiss A. The PI-3 kinase/AKT pathway and T cell activation: pleiotropic pathways downstream of PIP3. Immunol Rev 2003; 192: 7-20.
26. Plas DR, Talapatra S, Edinger AL, Rathmell JC and Thompson CB. AKT and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology. J Biol Chem 2001; 276: 12041-12048.
27. Franke TF, Hornik CP, Segev L, Shostak GA and Sugimoto C. PI3K/AKT and apoptosis: size matters. Oncogene 2003; 22: 8983-8998.
28. Matsuzawa A and Ichijo H. Stress-responsive protein kinases in redox-regulated apoptosis signaling. Antioxid Redox Signal 2005; 7: 472-481.
29. Anderson KE and Jackson SP. Class I phosphoinositide 3-kinases. Int J Biochem Cell Biol 2003; 35: 1028-1033.
30. del Peso L, Gonzalez-Garcia M, Page C, Herrera R and Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase AKT. Science 1997; 278: 687-689.
31. Gajewski TF and Thompson CB. Apoptosis meets signal transduction: elimination of a BAD influence. Cell 1996; 87: 589-592.
32. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E and Slingerland JM. PKB/AKT phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002; 8: 1153-1160.
33. Cross DA, Alessi DR, Cohen P, Andjelkovich M and Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-789.
34. Hay N. The AKT-mTOR tango and its relevance to cancer. Cancer Cell 2005; 8: 179-183.
35. Uddin S, Bavi P, Siraj AK, Ahmed M, Al-Rasheed M, Hussain AR, Ahmed M, Amin T, Alzahrani A, Al-Dayel F, Abubaker J, Bu R and Al-Kuraya KS. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma. Endocr Relat Cancer 2010; 17: 191-202.
36. Cheng SP, Yin PH, Chang YC, Lee CH, Huang SY and Chi CW. Differential roles of leptin in regulating cell migration in thyroid cancer cells. Oncol Rep 2010; 23: 1721-1727.
37. Brunet A, Datta SR and Greenberg ME. Transcription-dependent and -independent control of neuronal survival by the PI3K-AKT signaling pathway. Curr Opin Neurobiol 2001; 11: 297-305.
38. Datta R, Oki E, Endo K, Biedermann V, Ren J and Kufe D. XIAP regulates DNA damageinduced apoptosis downstream of caspase-9 cleavage. J Biol Chem 2000; 275: 31733-31738.
39. Huang CY, Yu HS, Lai TY, Yeh YL, Su CC, Hsu HH, Tsai FJ, Tsai CH, Wu HC and Tang CH. Leptin increases motility and integrin upregulation in human prostate cancer cells. J Cell Physiol 2011; 226: 1274-1282.
40. Uddin S, Bavi PP, Hussain AR, Alsbeih G, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Ahmed M and Al-Kuraya KS. Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. Carcinogenesis 2009; 30: 1832-1840.
41. Paik SS, Jang SM, Jang KS, Lee KH, Choi D and Jang SJ. Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. Ann Surg Oncol 2009; 16: 297-303.
42. Uddin S, Bu R, Ahmed M, Abubaker J, Al-Dayel F, Bavi P and Al-Kuraya KS. Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol Cancer 2009; 8: 74.
43. Choi JH, Park SH, Leung PC and Choi KC. Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. J Clin Endocrinol Metab 2005; 90: 207-210.
44. Uddin S, Bu R, Ahmed M, Hussain AR, Ajarim D, Al-Dayel F, Bavi P and Al-kuraya KS. Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large Bcell lymphoma. Leuk Lymphoma 2010; 51: 1305-1314.
45. Frankenberry KA, Skinner H, Somasundar P, McFadden DW and Vona-Davis LC. Leptin receptor expression and cell signaling in breast cancer. Int J Oncol 2006; 28: 985-993.
46. Akinci M, Kosova F, Cetin B, Aslan S, Ari Z and Cetin A. Leptin levels in thyroid cancer. Asian J Surg 2009; 32: 216-223.
47. Botella-Carretero JI, Alvarez-Blasco F, Sancho J and Escobar-Morreale HF. Effects of thyroid hormones on serum levels of adipokines as studied in patients with differentiated thyroid carcinoma during thyroxine withdrawal. Thyroid 2006; 16: 397-402.
48. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL and Caro JF. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295.
49. Cheng SP, Chi CW, Tzen CY, Yang TL, Lee JJ, Liu TP and Liu CL. Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma. Surgery 2010; 147: 847-853.
50. Mantzos F, Vanakara P, Samara S, Wosniak G, Kollia P, Messinis I and Hatzitheofilou C. Leptin receptor expression in neoplastic and normal ovarian and endometrial tissue. Eur J Gynaecol Oncol 2011; 32: 84-86.
51. Raef H, Alfadhli E, Al-Hajjaj A, Malabu UH, Al-Sobhi S, Rifai A and Al Nuaim A. High rate of persistent/recurrent disease among patients with differentiated thyroid cancer in Saudi Arabia: factors affecting nonremission. Ann Saudi Med 2008; 28: 277-281.
52. Duan C, Li M and Rui L. SH2-B promotes insulin receptor substrate 1 (IRS1)-and IRS2-mediated activation of the phosphatidylinositol 3-kinase pathway in response to leptin. J Biol Chem 2004; 279: 43684-43691.
53. Huang CY, Yu HS, Lai TY, Yeh YL, Su CC, Hsu HH, Tsai FJ, Tsai CH, Wu HC and Tang CH. Leptin increases motility and integrin upregulation in human prostate cancer cells. J Cell Physiol 2011; 226: 1274-1282.
54. Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG, Tsang BK and Cheng JQ. AKT phosphorylation and stabilization of Xlinked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004; 279: 5405-5412.
55. Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, Atizado V, Al-Dayel F, Belgaumi A, El-Solh H, Ezzat A, Bavi P and Al-Kuraya KS. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006; 108: 4178-4186.
56. Asselin E, Mills GB and Tsang BK. XIAP regulates AKT activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 2001; 61: 1862-1868.